Author/Authors :
Alexander V. Kachur، نويسنده , , William R. DolbierJr.، نويسنده , , Sydney M. Evans، نويسنده , , Chyng-Yann Shiue، نويسنده , , Grace G. Shiue، نويسنده , , Kirsten A. Skov، نويسنده , , Ian R. Baird، نويسنده , , Brian R. James، نويسنده , , An-Rong Li، نويسنده , , Alex Roche، نويسنده , , Cameron J. Koch، نويسنده ,
Abstract :
We report on the preparation of a hypoxia marker 2-(2-nitroimidazol-1[H]-yl)-N-(3-fluoropropyl)acetamide (EF1) and its 18F analog, 2-(2-nitroimidazol-1[H]-yl)-N-(3-[18F]fluoropropyl)acetamide ([18F]-EF1). Two methods for the preparation of 3-fluoropropylamine, the EF1 side chain, are described. [18F]-EF1 was prepared with a radiochemical yield of 2% by nucleophilic substitution of bromine in 2-(2-nitroimidazol-1[H]-yl)-N-(3-bromopropyl)acetamide (EBr1) by carrier-added 18F in DMSO at 120°C.
Our results demonstrate the preparation of clinically relevant amounts of [18F]-EF1 for use as a non-invasive hypoxia marker with detection using positron emission tomography (PET).
